Skystar Bio-Pharmaceutical to Present at the 2009 Roth Capital Partners China Conference

2009-10-05

疫苗

XI'AN, CHINA--(Marketwire - October 05, 2009) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company will present at the 2009 Roth Capital Partners China Conference on Wednesday, October 14, 2009 at 10:00 a.m. Eastern time. The conference is being held at the Fontainebleau Resort in Miami Beach, Fla. An audio and slide webcast of the live presentation will be available under the "Events and Presentations" page on the "Investor Relations" section of the Company's website at . An archived presentation will be available for 90 days. To request a one-on-one meeting or to be added to Skystar's email list, please contact Brandi Floberg at skystar@tpg-ir.com or call 212-481-2050. About Skystar Bio-Pharmaceutical Company Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit . To be added to the Company's email distribution for future news releases, please send your request to skystar@tpg-ir.com. Forward-looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. Contacts: The Piacente Group, Inc. Investor Relations Counsel Brandi Floberg (212) 481-2050 Email Contact Skystar Bio-Pharmaceutical Company Scott Cramer Director - U.S. Representative (407) 645-4433 Email Contact

机构